Ipsen Selects Kinaxis to Accelerate Supply Chain Planning
Delivering medicines to patients faster drives growth for European biopharmaceutical leader
Kinaxis Inc. (TSX:KXS), provider of RapidResponse®, a leading cloud-based supply chain management solution based on concurrent planning, today announced that Ipsen has selected Kinaxis® to manage the company’s global supply chain in support of the company’s SPEED initiative to achieve high business growth.
Ipsen, a global biopharmaceutical company focused on innovation and specialty care, is committed to discovering new solutions for debilitating diseases and improving quality of life for patients, and will deploy Kinaxis to manage worldwide inventory and gain complete visibility and control over the company’s product supply and demand. Kinaxis will help Ipsen reduce effective lead times to customer delivery by leveraging the product’s collaborative planning capability, helping eliminate stock shortages while shortening new product approval timelines – making new medicines available to patients that much more quickly.
“With RapidResponse and its powerful concurrent planning capabilities we will be able to account for every element impacting supply and demand in our global operation,” said Ronan Stephens, Senior Vice President, Global Supply Chain and External Manufacturing, Ipsen. “The ability to run ‘what-if’ scenarios with RapidResponse will help us better understand our supply chain and more accurately forecast changes in demand and related impacts on operations, end-to-end. Our decisions will be more informed, which will benefit both our business and, more importantly, those who rely on our vital products.”
“We are excited to be working with Ipsen to revolutionize its demand and supply chain planning processes to drive growth in support of its ‘Speed’ initiative. For Kinaxis, this is another indication of our rapidly growing customer base in Europe, and is yet another example of our continued growth in life sciences as we help transform how complex value chains are managed in the industry,” said John Sicard, Chief Executive Officer, Kinaxis. “Our product’s powerful concurrent planning capabilities will help Ipsen know sooner and act faster when fluctuations in supply or demand occur, helping them ensure that supply of their critical products is always available to patients when and where they need it.”
Kinaxis is central to Ipsen’s transformational supply chain management journey as the product will help launch and manage the distribution and availability of new product offerings in coming years.
Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to Kinaxis' growth opportunities and the potential benefits of, and demand for, Kinaxis’ products and services. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of Kinaxis' products and services compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. Kinaxis' actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of Kinaxis to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by Kinaxis with Canadian securities regulatory authorities. Kinaxis assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.